Intracerebral hemorrhage (ICH) represents 10-15% of all cerebrovascular events, and is associated with substantial morbidity and mortality. In contrast to ischemic cerebrovascular disease in which acute therapies have proven beneficial, ICH remains a more elusive condition to treat, and no surgical procedure has proven to be beneficial. Aspects pertinent to medical ICH management include cessation or minimization of hematoma enlargement, prevention of intraventricular extension, and treatment of edema and mass effect. Therapies focusing on these aspects include prothrombotic (hemostatic) agents, antihypertensive strategies, and antiedema therapies. Therapies directed towards the reversal of antithrombosis caused by antiplatelet and anticoagulant agents are frequently based on limited data, allowing for diverse opinions and practice styles. Several newer anticoagulants that act by direct thrombin or factor Xa inhibition have no natural antidote, and are being increasingly used for various prophylactic and therapeutic indications. As such, these new anticoagulants will inevitably pose major challenges in the treatment of patients with ICH. Ongoing issues in the management of patients with ICH include the need for effective treatments that not only limit hematoma expansion but also result in improved clinical outcomes, the identification of patients at greatest risk for continued hemorrhage who may most benefit from treatment, and the initiation of therapies during the hyperacute period of most active hemorrhage. Defining hematoma volume increases at various anatomical locations that translate into clinically meaningful outcomes will also aid in directing future trials for this disease. The focus of this review is to underline and discuss the various controversies and challenges involved in the medical management of patients with primary and antithrombotic-related ICH.
Introduction
Intracerebral hemorrhage (ICH) represents 10-15% of all cerebrovascular events [Sudlow and Warlow, 1997] and is associated with a 30-day mortality rate of approximately 40%, with an additional 40% of patients remaining disabled at 6 months [Counsell et al. 1995] Various medical strategies have been proposed and studied in the treatment of primary ICH from hypertensive or amyloid arteriopathies, including prothrombotic agents to create hemostasis in ruptured vessels, antihypertensive/normotensive treatments to limit perfusion pressures into damaged vessels, and antiedema medications to decrease perihematomal edema and mass effect.
The management of antithrombotic-associated ICH may allow for more goal-directed interventions (correction of abnormal laboratory values), but is frequently based on limited and inadequate evidence. The recent introduction of a newer generation of anticoagulants with novel mechanisms of action will inevitably provide even greater challenges to the management of patients with ICH. This article reviews the contemporary literature about the medical treatment of primary and antithrombotic-associated ICH, and explores current existing controversies and anticipated future challenges in the treatment of ICH.
Primary intracerebral hemorrhage
In patients with primary ICH, clinical and radiological determinants of outcome include patient age, clinical status upon presentation, ICH location and size, and intraventricular hemorrhage (IVH) [Hemphill et al. 2001 ]. Among these variables, only ICH size and IVH are amenable to intervention, given that intracerebral expansion and intraventricular extension may occur as a result of the dynamic nature of the hematoma [Steiner et al. 2006a; Brott et al. 1997 ]. Being that IVH represents a consequence of hemorrhage enlargement and hematoma size [Moussouttas et al. 2011; Hallevi et al. 2008] , the single most addressable target in ICH management becomes the limitation of hematoma expansion during the acute phase when continued active hemorrhage is most likely to occur [Davis et al. 2006; Brott et al. 1997 ]. Additional possible complications of any ICH include satellite hemorrhages, hydrocephalus, edema and mass effect (Figure 1 ).
Predictors of hematoma expansion
In an effort to identify patients at greatest risk for hematoma expansion, and therefore those that may most benefit from acute therapeutic interventions, various clinical, laboratory and radiological factors have been investigated and identified. Determinants of hematoma expansion have included anticoagulant (warfarin) use [Flibotte et al. 2004] , larger initial size [Broderick et al. 2007b] , irregular shape and density [Barras et al. 2009] , and serological evidence of systemic inflammation [Silva et al. 2005] . Contrast extravasation into the hematoma body, indicative of persisting vascular mural permeability and ongoing hemorrhage, has been identified as an independent predictor of hematoma enlargement and adverse outcomes [Almandoz et al. 2010; Goldstein et al. 2007; Wada et al. 2007 ].
Prothrombotic strategies
Prothrombotic strategies have centered around the use of recombinant activated factor VII (rF-VIIa), a compound originally used in the treatment of hemophilia [Roberts et al. 2004] . Upon injury to the endothelium, local release of thromboplastin and initial aggregation of platelets induce the conversion of VII to active VIIa, which converts factor X to Xa, thereby initiating the extrinsic coagulation cascade that results in thrombin generation and fibrin deposition [Roberts et al. 2004] . In an attempt to augment local thrombosis at the site of vessel rupture, and thereby decrease hemorrhage and hematoma expansion, rF-VIIa was studied in two major trials of primary ICH.
The initial phase II study was a randomized trial of rF-VIIa (40, 80 and 160 mg) versus placebo in patients diagnosed using computerized tomography (CT) within 3 h of onset [Mayer et al. 2005] . For the nearly 400 enrolled patients, mean treatment time was 167 min. The 80 mg and 160 mg doses resulted in decreased hematoma expansion (rF-VIIa 14% and 11% versus placebo 29%), and decreased rates of IVH and edema at 24 h. Decreases in 90-day mortality (18% versus 29%), and improved functional outcomes as measured by several grading scales were also observed in the active treatment arms. However, more systemic thrombotic events occurred with rF-VIIa (7% versus 2%), mostly in patients receiving the 160 mg dose.
The similar phase III FAST study tested rF-VIIa (20 and 80 mg) versus placebo, enrolled over 800 patients, and administered treatment within a mean time of 160 min [Mayer et al. 2008] . Again a decrease in hematoma expansion was noted for the 80 mg group (11% versus 26%), yet this time no difference was noted in IVH rate, edema volume, mortality or disability (26% and 29% versus 24%). Possible reasons for the contrasting negative findings have included unexpected low mortality and disability in the placebo group (19% and 24%, respectively), more frequent IVH in patients receiving rF-VIIa (38% versus 29%), and more thrombotic (mostly coronary) complications in those receiving rF-VIIa (8% versus 4%).
A post-hoc analysis of the FAST trial identified a subgroup of patients in whom rF-VIIa 80 mg/kg may be beneficial [Mayer et al. 2009 ]. Patients younger than 70 years, with an ICH volume less than 60 ml, an IVH volume less than 5 ml, and time to treatment up to 2.5 h were found to have a lower chance of a poor outcome (Rankin score 5-6) compared with placebo (odds ratio 0.28; 95% confidence interval 0.08-1.06). A greater mean reduction in hematoma volume was also noted in comparison to the entire study group (7.3 ml versus 3.8 ml; p ¼ 0.02).
These findings, however, are yet to be verified in a prospective trial.
Antihypertensive strategy
Antihypertensive strategies have evolved on the premise that perfusion pressure inside the vessel lumen may promote continued hemorrhage from regions with compromised mural integrity and local loss of autoregulation [Morgensetern et al. 2010 ]. However, the exact role of hypertension following acute ICH has never been definitively elucidated [Jauch et al. 2006 ] and controversy exists as to whether elevated pressures contribute to hematoma expansion, result from the hematoma causing compression of central structures and intracranial pressure elevations, or simply represent a marker of severity and worse prognosis [Morgensetern et al. 2010] . To date there have been two randomized trials assessing whether various ranges of systemic pressures reduce hematoma expansion and provide benefit in patients with acute ICH.
The INTERACT study enrolled over 400 patients presenting with systolic pressures of 150-180 mmHg, who were randomized within 6 h of onset to conservative (systolic <140 mmHg) versus liberal (systolic <180 mmHg) control [Anderson et al. 2008] . Goal pressures were to be achieved within 1 h of starting intravenous nicardipine, and were maintained for 24 h. Mean initial systolic pressures were similar in the two groups, and overall mean time to treatment was 4.5 h from onset. At 24 h, less ICH expansion was seen in the conservative arm (14% versus 36%), as well as less substantial enlargement defined as volume increase greater than 33% (15% versus 33%), but no difference was observed in edema volume on day 3 or on the clinical outcome mortality/disability (48% versus 49%) at 90 days . The anticipated INTERACT II study will be an open-label but assessor-blinded trial that will randomize 2800 patients presenting with systolic pressures of 150-220 mmHg to two treatment arms (systolic <140 versus <180 mmHg) within 6 h of ICH onset for a period of 7 days. The primary outcome will be 90-day mortality/dependency, while secondary outcomes will assess treatment within 4 h, levels of disability and quality of life.
The ATACH study randomized 80 patients with systolic pressures greater than 170 mmHg to one of three target systolic pressures within 6 h of onset using intravenous nicardipine for 24 h [ATACH Investigators, 2010] . Preliminary results demonstrated greater rates of treatment failure, adverse events, neurologic worsening, and mortality in the most aggressively treated group. Threemonth outcomes comparing dichotomized groups above and below the medians for two treatment parameters (systolic reduction at 6 h and systolic reduction area under the curve) revealed trends towards improved radiographical and clinical outcomes, but no definite advantage to aggressive treatment [Qureshi et al. 2010 ].
Various theories have been proposed to explain the failure of antihypertensive therapy to improve clinical outcomes despite mitigating hematoma expansion. Low baseline clinical severity, small initial hematoma volumes, relatively minor decreases in hematoma enlargement from active treatment, lack of impact on perihematomal edema, possible neurological deterioration from induced ischemia in vulnerable regions, inadequate study power, and hypertension as a consequence and not cause of ICH expansion have all been postulated [Anderson et al. , 2008 ATACH Investigators, 2010; Qureshi et al. 2010] .
Perihematomal edema and inflammation
Studies on the treatment of perihematomal edema and inflammation have used hyperosmolar and steroidal agents in an attempt to minimize or reduce regional mass effect and tissue injury. The variety of agents used speaks to the uncertainty that exists regarding the exact nature of the edema -extruded serum from hematoma coagulation and contraction, vasogenic edema from local disruption of capillary membranes, or cytotoxic cellular injury [Hoff and Xi, 2003 ]. Controversy also exists as to whether the diffusion restricted areas of edema on magnetic resonance imaging (MRI) represent cytotoxic edema secondary to compromised microvascular perfusion (in which case, antihypertensive therapy may be detrimental) or cytotoxic edema due to structural and biochemical damage from the hemorrhage.
Perfusion studies that demonstrated hypoperfusion to the perihematomal area were interpreted as representing penumbra with potential for ischemia [Siddique et al. 2002] . However, histological investigations revealed mitochondrial dysfunction without ischemia [Kim et al. 2006 ], implying that the reduced perfusion and metabolism may indicate tissue hibernation [Qureshi et al. 2009 ]. MRI studies have characterized the perihematomal edema as predominantly extracellular [Carhuapoma et al. 2000] , with lesser areas of cytotoxic edema unrelated to the degree of hypoperfusion and thus unlikely ischemic [Olivot et al. 2010] . Whether edema volume actually impacts clinical outcome remains to be determined [Arima et al. 2009; Gebel et al. 2002] , thus possibly negating the need for future trials of antiedema agents in patients without substantial mass effect or intracranial hypertension.
Only two studies have tested the utility of dexamethasone in patients with ICH. The first was limited by very small patient numbers, partial open-label treatment allocation, unavailability of modern imaging techniques, inclusion of patients with hemorrhagic infarction, and the use of nonstandardized clinical grading scales [Tellez and Bauer, 1973] . The second enrolled larger numbers, randomized patients in a blinded fashion, included only patients with supratentorial ICH diagnosed by CT, and stratified patients according to Glasgow Coma Scale score [Poungvarin et al. 1987] . No differences in mortality were noted, while greater rates of infection and hyperglycemia occurred with dexamethsone. The study was terminated prematurely.
In the first study of hyperosmolar therapy, 216 patients with primary supratentorial ICH were randomized within 24 h of onset to intravenous glycerol versus saline for 6 consecutive days. No difference in 180-day outcome was seen, yet anemia due to hemolysis occurred with glycerol [Yu et al. 1992] . Mannitol (20% 100 ml) was tested in a randomized, controlled trial of 128 patients presenting within 6 days of a primary supratentorial CT confirmed ICH [Misra et al. 2005 ]. Thirty-day mortality and 90-day functionality did not differ between the two groups. Physiological studies have failed to demonstrate an advantage to treatment with mannitol in terms of augmenting regional perfusion following ICH [Kalita et al. 2004] .
Data from animal models and human subjects suggest that hypothermia 35 8 C may reduce perihematomal edema, and thus possibly concurrent neurotoxicity, via enhancement of endothelial integrity, anti-inflammatory actions and neuroprotective properties [Kollmar et al. 2010; MacLellan et al. 2006 ]. Potential adverse developments, however, may include rebound edema and intracranial pressure increase [Schwab et al. 2001] , and various multisystem complications [Polderman and Herold, 2009] . Whereas hypothermia may also theoretically attenuate any evolving perihematomal ischemia [Kollmar et al. 2002] , the hypertension that typically accompanies hypothermia may risk ICH enlargement [MacLellan et al. 2004] . No randomized controlled trials have been performed.
Summary and future strategies
In conclusion, contemporary studies have demonstrated the ability of prothrombotic and antihypertensive modalities to reduce ICH enlargement, but not to alter clinical outcome [Qureshi et al. 2010; Anderson et al. 2008; Mayer et al. 2008 Mayer et al. , 2005 . This paradox may be explained by the magnitude of hematoma volume difference achieved between the treatment and placebo arms. In all studies performed, absolute volume differences between treatment groups were typically on the order of 2-5 ml, which when compared with mean hematoma volumes of 20-30 ml represents a very small fraction of the entire hemorrhagic mass.
Recent articles have attempted to define an absolute or relative volume increase which may reliably determine clinical worsening among patients with ICH, and which may be suitable for study as an endpoint in randomized trials [Dowlatshahi et al. 2011] . Absolute volume increases of 12 ml or more, and not relative increases, were found to have the best predictive value for clinical deterioration [Dowlatshahi et al. 2011] . The authors correctly concluded that many patients with ICH may not benefit from acute therapies because of the rarity of cases in which hematoma expansion exceeds 12 ml. They propose that future studies may require very large numbers of patients to demonstrate any treatment effect, or may need to selectively include only those patients at greatest risk for substantial expansion [Dowlatshahi et al. 2011] .
Omitted from this informative review was the role that hemorrhage location and intraventricular extension play in determining clinical worsening. Posterior fossa lesions of even 3 cm diameter may cause substantial functional compromise and clinical deterioration by local compression of adjacent structures or by obstructive hydrocephalus [Morgensetern et al. 2010 ]. In addition, hemorrhages in deep paraventricular areas (thalamus and caudate head) are typically smaller and undergo less expansion than those of the lenticular nuclei or lobar locations, yet result in similar outcomes [Moussouttas et al. 2011 ]. As such, ICH location must be considered a crucial factor in defining the 'critical' amount of hematoma volume that determines clinical worsening. To date, no clinical studies have addressed this issue.
Therefore, whereas cerebral ischemia represents an acute process for which successful treatment may be instituted during the first few hours following onset, ICH may represent a 'hyperacute' process that may necessitate treatment within the first 1 or 2 h of onset. The small increases in hematoma volumes observed in major clinical trials of patients diagnosed within 3-6 h [Qureshi et al. 2010; Anderson et al. 2008; Mayer et al. 2008 Mayer et al. , 2005 and the frequent evidence of IVH upon initial scanning [Steiner et al. 2006a ] support the concept of greatest hematoma expansion within a very narrow and early time frame.
Antithrombotic-related intracerebral hemorrhage
Risk factors for antithrombotic ICH have mostly been studied in the context of warfarin use, and include age, hypertension, leukoaraiosis, amyloid angiopathy, and intensity of anticoagulation [Broderick et al. 2007a ]. Evidence-based guidelines regarding the use of reversing agents and hematologous transfusions for the management of ICH due to antithrombotic drugs are limited by incomplete and inadequate data, which has allowed for various therapeutic options and for diverse treatment preferences.
Hematoma characteristics
In contrast to primary ICH, antithrombotic hemorrhages (and, in particular, warfarin-related ICHs) demonstrate larger initial volumes and greater hematoma enlargement, likely due to more pronounced and prolonged extravasation [Cucchiara et al. 2008] . Antithrombotic ICHs are also more irregular in contour such that visual estimation of volume may be most accurately approximated by the equation ABC/3 (instead of ABC/2, which is typically used for nonantithrombotic hematomas) [Huttner et al. 2006b] , where ABC represents the product of each of the longest three-dimensional diameters [Kothari et al. 1996 ]. Finally, hemorrhages related to antithrombotics frequently exhibit distinct fluid levels [Gebel et al. 1998 ], indicating separation of plasma and cellular components because of impaired thrombus formation [Ichikawa and Yanagihara, 1998 ], and may be multicompartmental [Gebel et al. 1998 ]. Theoretically, less edema may develop as a result of impairment in the thrombin generation, which typically increases vascular permeability [Sansing et al. 2003 ], but this has not consistently been observed ].
Antiplatelet agents
Controversy exists over whether ICH in the setting of antiplatelet use warrants platelet transfusion because the literature is conflicting as to whether antiplatelet agents even contribute to hematoma expansion or to adverse outcomes. Evidence that antiplatelet agents increase hematoma expansion and worsen outcome [Yildiz et al. 2011; Creutzfeldt et al. 2009; Toyoda et al. 2009 Toyoda et al. , 2005 Lacut et al. 2007; Sorimachi et al. 2007; Saloheimo et al. 2006; Roquer et al. 2005] is countered by studies that report no increase in hematoma volume or worsened outcome [Moussouttas et al. 2010; Sansing et al. 2009; Ishibashi et al. 2008; Broderick et al. 2007b; Foerch et al. 2006] , and by animal studies showing no differences in volumes or outcomes [Lauer et al. 2011 ].
These contrasting data may be attributed to differences in study methodology (for example, inclusion or exclusion of posterior fossa hemorrhages which may be predisposed to intraventricular extension yet undergo limited enlargement from anatomic restrictions, visual versus computerized hematoma volume measurement techniques, and outcome measures of >33% versus any measurable volume increase). However, the discrepancies may also be due to unreliability of reported antiplatelet use, the variety of agents used at different doses, and interindividual differences in antiaggregant activity and resistance [Naidech et al. 2009a ]. To date, retrospective studies have failed to show benefit from platelet transfusion in patients with ICH on antiplatelet agents [Ducret et al. 2010; Creutzfeldt et al. 2009 ]. Presently, only small observational studies have assessed the impact of platelet inhibition, as measured by aggregometry assays, upon ICH enlargement and clinical outcome. One study identified greater hematoma expansion in patients with impaired platelet activity, as well as worse outcomes at 90 days compared with those with normal platelet action [Naidech et al. 2009c] . A second study associated reduced platelet activity with the occurrence of IVH, greater ICH score, and greater risk for mortality [Naidech et al. 2009b ]. The investigators of these studies also identified greater platelet inhibition among patients taking combination antiplatelet regimens compared with those on single agents only [Naidech et al. 2009a ].
Unfortunately, unlike measures of anticoagulant activity [for example, international normalized ratio (INR) for warfarin or partial thromboplastin time (PTT) for heparin], no consistently reliable or globally validated method exists for quantifying the antiaggregant activity induced by antiplatelet agents [Breet et al. 2010] , and therefore no means exists by which to select those patients who may be most at risk for continued hemorrhage, or those who may most benefit from transfusion therapy. Currently, the use of platelet transfusions in patients with ICH is unproven and is considered investigational [Morgensetern et al. 2010] . Potential complications of transfusion that must be considered include volume overload, transfusion reactions, anaphylaxis, acute lung injury, and infection [Refaai et al. 2011] .
Heparin and warfarin
In reversing heparin anticoagulation, protamine remains the single most effective and only needed treatment, which can rapidly and completely normalize PTT following administration [Hirsh and Raschke, 2004] . Conversely, several treatment options exist for the management of warfarin-related ICH with elevated INR, including cobalamin, fresh frozen plasma (FFP), prothrombin complex concentrates (PCCs) and rF-VIIa. In the absence of randomized, controlled studies, diverse and varied opinions exist regarding the most appropriate therapy or combination of therapies ]. In contrast to antiplatelet agents, warfarin use has been convincingly connected to hematoma expansion and adverse outcome [Cucchiara et al. 2008; Flibotte et al. 2004 ].
Cobalamin counteracts warfarin inhibition of synthetic enzymes, and provides hemostatic protection beyond the limited lifespan of administered factors ]. Intravenous cobalamin reverses coagulopathy faster than oral dosing [Watson et al. 2001] , and subcutaneous administration is discouraged due to unpredictable absorption [Raj et al. 1999] . A dose of 10 mg is generally recommended [Morgensetern et al. 2010] , and risk of anaphylaxis from intravenous administration is considered to be low [Fiore et al. 2001 ]. Since reversal takes several hours [Watson et al. 2001] , concurrent administration of coagulation factors is essential. In one study, normalization of INR by 2 h occurred in 84% of patients given PCC, in 39% of those given FFP and in 0% of those given cobalamin [Huttner et al. 2006a ]. Hematoma expansion occurred in 19%, 33% and 50% respectively.
Among coagulation factor replenishing agents, PCCs and rF-VIIa are capable of normalizing INR within minutes, whereas FFP may require hours [Morgensetern et al. 2010; Steiner et al. 2006b ]. This may be because of the variable concentrations of coagulation factors provided by FFP, and therefore to variable completeness of factor repletion [Broderick et al. 2007a] . Treatment delays may also be encountered in the time needed for preparation and infusion of FFP [Bershad and Suarez, 2010] . Failure to achieve hemostasis following INR correction with FFP has also been observed [Lee et al. 2006 ], possibly due to persistently low factor IX levels [Makris et al. 1997 ]. FFP may also be associated with diminishing gains, whereby large amounts of FFP result in negligible INR changes when the INR is 1.5 [Holland and Brooks, 2006] . Because FFP administration can be complicated by volume overload and heart failure, transfusion reactions and anaphylaxis, and the potential for infectious transmission, some authorities have suggested alternative agents ].
As a recombinant preparation composed of one coagulation protein, rF-VIIa lacks many of the factors inhibited by warfarin, and thus may not completely reverse warfarin anticoagulation.
Studies on human subjects have demonstrated an inability for rF-VIIa to reverse warfarininduced hemorrhagic diathesis despite normal INR [Skolnick et al. 2010] , and experimental studies have confirmed the ability of rF-VIIa to correct the INR yet fail to restore thrombin generation [Tanaka et al. 2008] . The transient duration of activity and possible need for repeated dosing, in conjunction with the known systemic thrombotic complications, may also pose a substantive risk when using rF-VIIa [Broderick et al. 2007a] . As a result of these limitations, neurovascular societal guidelines have discouraged the use of this drug [Morgensetern et al. 2010] .
PCCs are an admixture of various coagulation factors, the exact composition and concentration of which varies depending on the specific formulation. However, all contain those factors inhibited by warfarin (II, VII, IX and X), and some provide a more 'physiologically balanced' preparation that includes inhibited anticoagulants (proteins C and S) [Bershad and Suarez, 2010] . Like rF-VIIa, PCCs may provide for rapid correction of INR [Dickneite, 2007] yet may also provide more complete reversal of coagulopathy [Dickneite, 2007] and less risk for thromboembolic and ischemic complications [Morgensetern et al. 2010; Leissinger et al. 2008] . PCC use may also avoid many of the complications associated with FFP [Bershad and Suarez, 2010] . As a result, leading neurovascular organizations have increasingly recommended PCCs for reversal of warfarin anticoagulation [Morgensetern et al. 2010] .
Newer anticoagulants
The newer generation anticoagulants which act by direct thrombin inhibition or by direct Xa inhibition are administered by intravenous or oral route, and are variably indicated in the treatment of thrombotic conditions (venous thromboembolization and heparin-induced thrombocytopenia) and in preventing atrial fibrillation embolization [Levy et al. 2010] . These agents will be increasingly seen in the setting of ICH because of the increasing use of oral medications which, unlike warfarin, do not require routine serological monitoring, and as a result of an aging population are more predisposed towards atrial fibrillation and cerebral amyloid angiopathy [Vernooij et al. 2008; Go et al. 2001] . The major challenge with these new agents will be reversal of anticoagulation in the setting of ICH, since no natural antidote or reversing medication exists for these compounds [Levy et al. 2010 ].
Among the direct thrombin inhibitors are argatroban and the hirudin family of anticoagulants which are indicated in the setting of heparininduced thrombocytopenia [Levy et al. 2010] , and dabigatran which recently demonstrated superior effectiveness and improved safety over warfarin in the outpatient management of atrial fibrillation and deep vein thrombosis/pulmonary embolism Schulman et al. 2009 ]. Of the direct factor Xa inhibitors, apixaban has shown greater efficacy over aspirin, and rivaroxaban a better safety profile than warfarin in patients with atrial fibrillation at risk for cardioembolization [Cleland et al. 2011; Connolly et al. 2011 ]. Low molecular weight heparin agents, heparinoids and fondoparinux, by inhibiting Xa via antithrombin, have been in use as substitutes for heparin in deep vein thrombosis prophylaxis, or for the treatment of venous thromboembolic disease [Levy et al. 2010] .
Currently, no medication or transfusion is capable of completely neutralizing the anticoagulant activity of the direct thrombin or (direct or indirect) factor Xa inhibitors, potentially rendering patients with ICH at great risk for continued hemorrhage, hematoma expansion, intraventricular extension, and added morbidity and mortality. In addition to possibly administering oral charcoal to any patient recently ingesting oral anticoagulants [Johnson & Johnson, New Brunswick, NJ; Van Ryn et al. 2009; Bristol Myers Squibb, New York, NY; , empiric transfusion of plasma coagulation products or recombinant coagulation factors may be considered [Van Ryn et al. 2010] . Given the more reliable composition of PCCs, and greater concentration of thrombin and factor X, PCCs may be preferred over FFP or rF-VIIa. Importantly, the pharmacokinetic properties for some of these agents may allow a certain degree of hemostasis and partial control of hemorrhage to be achieved. Specifically, the degree of protein binding for any given agent may determine the extent to which removal by means of hemodialysis may be feasible and possibly advantageous. Since heparinoids [Pfizer, New York, NY; hirudin-like agents [Berlex, Montville, NJ; 2004] and dabigatran [Boehringer Ingelheim, Ingelheim, Germany; possess relatively low or no protein binding, as opposed to other direct or indirect thrombin and factor Xa inhibitors, hemorrhage in conjunction with these agents may theoretically be more likely to respond to serologic extraction by dialysis [Van Ryn et al. 2010; Stratmann et al. 2004] . Unfortunately, the time required to place central access and administer hemodialysis may prove to be a costly limitation.
Monitoring the anticoagulant activity and effectiveness of reversal for the newer (and older) anticoagulants may be accomplished by measuring anti factor Xa activity for the direct and indirect Xa inhibitors, and by measuring PTT for the direct thrombin inhibitors. Dabigatran may also be monitored using the thrombin time assay, which provides the most linear measure of activity [Boehringer Ingelheim, 2010] , and rivaroxaban may be monitored by prothrombin time level but not INR, which is calibrated only for warfarin [Johnson & Johnson, 2009] . Table 1 provides a list of the laboratory tests that may be used to quantify anticoagulation, and the reversal agents for each antithrombotic drug.
Conclusions and future research
Substantial deficiencies persist in evidence-based directives on the management of patients with antithrombotic related ICH. For antiplatelet agents, a standardized and validated method for measuring platelet inhibition from agents with different modes of action is desperately needed, not only for assessing treatment efficacy in preventing vascular thrombotic events [Breet et al. 2010 ], but also for definitively determining whether the degree of antiaggregant activity correlates to ICH expansion [Naidech et al. 2009a ].
If such a correlation is determined, then randomized trials comparing platelet transfusion to supportive therapy will be needed to conclusively delineate the advantages and/or detriments incurred by transfusion.
Despite theoretical advantages and disadvantages among the various hemotogenous and reconstituted coagulation factor formulations available, sufficient clinical equipoise exists to justify a randomized trial comparing each of the major products, preferably in combination with cobalamin, so as to minimize excessive repeated administrations. Clinical, radiological (hematoma enlargement), and laboratory (INR) outcome measures will be imperative to determine the effectiveness of these therapies, and the reliability of commonly available serological coagulation tests. Documentation of adverse outcomes such as volume overload, immune reactions, infectious complications, and thrombotic events will be equally important.
For the new direct thrombin or factor X inhibitors, research to produce reversing agents is urgently needed given the increasing use of these anticoagulants and the inevitable cerebral and systemic hemorrhages that will ensue. Accurate reporting and comprehensive analysis of postmarketing data for these products is eagerly awaited, and must be compared against available information for the alternative and more traditional therapies, warfarin and aspirin. Subsequent studies to determine the impact of these antidotes in the setting of ICH will then be needed.
For any study of any antithrombotic-reversing modality, optimum quantification of dynamic hematoma evolution must be achieved, possibly by including only supratentorial ICH (or by dividing hemorrhages according to location), by employing computerized methods for comparing initial and subsequent hematoma volumes, and by analyzing final hematoma volume as a continuous and nominal variable (for example, volume increase >33%). Obtaining information regarding impact upon perihematomal edema or in inducing cerebral ischemia will also be of interest.
Reintroducing antithrombotics after intracerebral hemorrhage
In patients with ischemic cerebrovascular disease, the decision on whether to reinstitute antithrombotic therapy following ICH entails careful consideration of the relative risks for thrombosis versus hemorrhage. Risk stratification must be based on the type and severity of ischemic disease, on the underlying cause of ICH, and on the added hemorrhage risk from antithrombosis. Annual risk for recurrent cerebral ischemic events depends on the mechanism involved and the number of coexisting comorbidities, and ranges from 7% to 15% [Sacco et al. 2006 ]. Conversely, the yearly risk of hypertensive ICH recurrence is approximately 2% [Bailey et al. 2001] whereas that due to amyloid angiopathy ranges from 5% to 15%, depending on genetic predisposition [O'Donnell et al. 2000 ]. While risk of ICH recurrence does not appear to be increased by aspirin [Viswanathan et al. 2006 ], the risk may be tripled by warfarin [Vermeer et al. 2002] .
For atrial fibrillation patients with lobar ICH, the risk of recurrent hemorrhage with warfarin may exceed that of embolization [Eckman et al. 2003 ], leading some authorities to recommend antiplatelet agents [Morgensetern et al. 2010 ]. The presence and quantity of microhemorrhages as detected by gradient-echo MRI may indicate and quantify risk for recurrent ICH in such situations, and aid in risk assessment [Fan et al. 2003 ]. The newer oral anticoagulants that carry a lower risk for primary ICH than warfarin (;0.2% versus 1% per year) [Hart et al. 1995] may impact the decision on whether to restart anticoagulation, but rates of recurrent hemorrhages from these agents have yet to be determined. The timing of antithrombotic reintroduction following ICH is also a topic of uncertainty, with guidelines generally suggesting an abstinence period of 1-2 weeks for antiplatelet agents and 3-4 weeks for oral anticoagulants [Morgensetern et al. 2010] .
Surgical management
The largest randomized study to assess the role of hematoma evacuation, STICH, enrolled 1033 patients with supratentorial ICH of at least 2 cm to early surgery (median 30 h from onset) versus medical treatment alone [Mendelow et al. 2005] . Patients were eligible if clinical equipoise existed regarding the best treatment strategy, crossover was permitted in the event of neurological deterioration, and method of evacuation was determined by the involved surgeon. In the medical and surgical groups, evacuation was ultimately performed in 94% and 26% of patients, by craniotomy in 85% and 75% of cases, and with 6% needing reevacuation in each group. The primary outcome was functional status at 180 days relative to an admission prognosis score based on age, clinical condition and hematoma size. No differences were observed in favorable outcome from the primary endpoint measure (24% versus 26%), or in mortality between the two groups (37% versus 36%). Subgroup analysis from STICH indicated a possible advantage to surgery in patients not in a coma with lobar hemorrhages, and in those with hematomas up to 1 cm from the cortical surface [Mendelow et al. 2005 ]. The ongoing STICH II trial will assess the role of early surgery (<48 h) in patients with lobar ICH less than 1 cm from the cortex surface and no IVH. Limitations to STICH include lack of true randomization given inclusion by the clinical uncertainty principle, inter-institutional variability in determining clinical equipoise, the relatively late timing of surgery, and the large amount of crossover from the medical arm to the surgical group. In a smaller randomized trial of patients with subcortical/ deep hemorrhages of at least 30 ml randomized to hematoma removal or medical treatment within 8 h of onset, surgery resulted in improved outcomes for patients not in a coma with hematomas less than 80 ml (33% versus 9%), with no difference in mortality [Pantazis et al. 2006 ].
Recently, interest has developed in less invasive stereotactic endoscopic aspiration techniques (variably infusing fibrinolytics), which reduce the likelihood of cerebral injury from surgery. The ongoing MISTIE trial is a dose finding and safety study of intrahematomal tissue plasminogen activator (tPA) infusion in patients with supratentrial ICH greater than 25 ml and symptoms within 72 h. In a related study, CLEAR-IVH will randomize patients with ICH and IVH who present within 24 h with a supratentorial hematoma less than 30 ml to 1-3 mg of tPA or saline via ventriculostomy. Primary endpoints will include mortality and complication rate for MISTIE, and rate of ventricular hemorrhage resolution for CLEAR-IVH. Finally, despite the absence of trial-based evidence, surgical evacuation is generally recommended for posterior fossa (cerebellar) hematomas that are 3 cm in diameter and causing clinical deterioration, stem compression or obstructive hydrocephalus [Morgensetern et al. 2010] .
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